Latest News and Press Releases

the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL®.

Autolus announced its operational and financial results for the third quarter ended September 30, 2025

Data from a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus will be presented.

Autolus announced its operational and financial results for the second quarter ended June 30, 2025.

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 E

Autolus will participate in upcoming investor conferences.

Autolus will present in a fireside chat at the Needham Healthcare Conference on Wednesday, April 9, 2025.

Autolus announces recent updates and financial results for the full year ended December 31, 2024.

Autolus will report Q4 and FY 2024 financial results and operational updates on March 20, 2025.

Autolus will participate in two upcoming investor conferences: Jefferies Biotech on the Beach and Leerink Global Biopharma Conference.